Morgan Stanley Reiterates Overweight on 10x Genomics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has reiterated an Overweight rating on 10x Genomics (NASDAQ:TXG) and maintained a $65 price target.

August 07, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on 10x Genomics and maintained a $65 price target, indicating a positive outlook for the company.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. An Overweight rating suggests that the analyst believes the company's stock will outperform the market, while a maintained price target indicates stability in the company's perceived value. This could lead to increased investor confidence and a potential rise in TXG's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100